<DOC>
	<DOC>NCT01544361</DOC>
	<brief_summary>This is a Phase 1 study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI7814 in healthy adult subjects.</brief_summary>
	<brief_title>A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers</brief_title>
	<detailed_description>This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI7814 in healthy adult male subjects and female subjects of non-childbearing potential.</detailed_description>
	<criteria>Aged 18 years up to and including 49 years at the time of first dose of investigational product Healthy by medical history, physical examination, and laboratory studies Body weight 50125 kilogram (kg); body mass index 19.032.0 kilogram per square meter (kg/m^2) (inclusive) Females must be of nonchildbearing potential. Exclusion criteria: Any acute illness within 30 days of screening Concurrent enrollment in another clinical trial The subject has a positive drug/alcohol screen at screening or Day 1 Pregnancy Current cigarette smokers History of cancer other than nonmelanoma skin cancer or in situ carcinoma of the cervix treated with apparent success Use of immunosuppressive medications Subjects who have an unresolved infection with any Neisseria species Subjects who have had their spleen removed for any reason.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Healthy subjects</keyword>
	<keyword>MEDI7814</keyword>
	<keyword>FTiH</keyword>
</DOC>